• Abstract and Figures
• Public Full-text

Acta Pharmaceutica Sinica B 2012;2(6):588–597 Institute of Materia Medica, Chinese Academy of Medical Sciences Chinese Pharmaceutical Association Acta Pharmaceutica Sinica B www.elsevier.com/locate/apsb www.sciencedirect.com ORIGINAL ARTICLE Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARc Lijian Zhanga,y, Kang Tiana,y, Yongqiang Lib,y, Lei Leic, Aifang Qina, Lijuan Zhanga, Hongrui Songa, Lianchao Huob, Lijing Zhangb, Xiaofeng Jinb, Zhufang Shenc, Zhiqiang Fengb,n aSchool of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China bInstitute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China cBeijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China Received 29 May 2012; revised 20 September 2012; accepted 9 October 2012 KEY WORDS Abstract A series of novel phenyl-urea derivatives which can simultaneously activate glucokinase (GK) and peroxisome proliferator-activated receptor g (PPARg) was designed and prepared, and Type 2 diabetes; GK activators; their activation of GK and PPARg was evaluated. The structure–activity relationships of these PPARg agonists; compounds are also described. Three compounds showed potent ability to activate both GK and Dual action PPARg. The possible binding mode of one of these compounds with GK and PPARg were predicted by molecular docking simulation. & 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and hosting by Elsevier B.V. All rights reserved. nCorresponding author. Tel.: þ86 10 63189351. E-mail address: [email protected] (Zhiqiang Feng). yThese authors contributed equally to this work. Peer review under responsibility of Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. 2211-3835 & 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and hosting by Elsevier B.V. All rights reserved. http://dx.doi.org/10.1016/j.apsb.2012.10.002 Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARg 589 1. Introduction ligand-activated transcription factors that offer a promising therapeutic approach for metabolic syndrome6. Activation of Type 2 diabetes (T2D), a complex and chronic disease PPARg by insulin-sensitizing thiazolidinedione (TZD) drugs7,8 characterized by hyperglycemia, is becoming more prevalent. leads to improve insulin action in muscle and liver. Several It was estimated that 366 million people will be afflicted with groups have described various synthetic small molecules as diabetes worldwide by 2030 and 95% of them are T2D1. There PPARg agonists (Fig. 2). mainly are three contributing factors leading to hyperglyce- Based on the above understanding of GK and PPARg,a mia, including reduction of insulin secretion from pancreatic drug able to simultaneously activate both GK and PPARg b-cells2, decreased tissue sensitivity to insulin and dysregulated would be expected to have a strong antihyperglycemia effect hepatic glucose metabolism. Although many antihyperglyce- by promoting insulin secretion, modulating hepatic glucose mia drugs have been developed, the therapeutic effects of the balance, and decreasing insulin resistance. commercially available single target drugs for T2D are Our design of compounds with dual action as both GK unsatisfactory as those drugs address only a part of the disease activators and PPARg agonists is based on the assembly of or a specific stage of T2D, and can induce drug resistance. ligand-based pharmacophores. We started from the fusion of a Therefore, it is necessary to develop multiple-target hypogly- GK activator 1 reported by Prosidion/OSI, and a PPARg cemic drugs with more widespread therapeutic effect. agonist 7 reported from Dainippon Sumitomo, to form the Glucokinase (GK), a glucose-phosphorylating enzyme and compound structure 11 with dual pharmacophores (Fig. 3). member of the hexokinase family,ismainlyexpressedintheliver Though these two compounds 1 and 7 are different in shape, and pancreatic b-cells. It is a potential therapeutic targets for they share the same disubstituted phenyl scaffold. We used the T2D3,4, as activation of GK not only promotes glycogen synthesis phenyl-urea structure of GK activator 1 as the parent compound but also enhances insulin secretion from pancreatic b-cells. Hence, backbone and added the pharmacophore of 7 and various the development of GK activators to lower blood glucose and nitrogen heteroaromatic groups to it, generating structure 12 normalize insulin secretion is a promising area of current research with three groups, R1,R2,andR3 that remained modifiable. for treating T2D. Several groups have described various synthetic Based upon this template, a series of phenyl-urea derivatives small molecules that act as GK activators (Fig. 1)5. were designed, prepared and evaluated for ability to activate GK Peroxisome proliferator-activated receptors (PPARs) exist and PPARg. Some of these compounds showed potent ability to as three isoforms (PPARa, PPARb and PPARg) and are activate both GK and PPARg simultaneously. Figure 1 Structures of some GK activators reported and their pharmacophores (moieties in blue). Figure 2 Structures of some PPARg agonists and their pharmacophores (moieties in blue). 590 Lijian Zhang et al. Figure 3 Design strategy for GK/PPARg dual-target ligands. Scheme 1 Synthesis of compounds 17a–f and 18a–f. Reagents and conditions: (a) K2CO3,DMF,801C, 6 h; (b) MeOH, 10% Pd-C, rt, 6–8 h; (c) R1Br, K2CO3, DMF, 80 1C, 4–8 h; (d) aldehyde, AcOH, EtOH, 70 1C, 4–8 h, and then NaBH4,601C, 10 h and (e) MeCN, 22 or 23, reflux. Scheme 2 Synthesis of compounds 22 and 23. Reagents and conditions: (a) K2CO3, 2-aminothiazole or 2-amino-benzothiazole, MeCN, reflux. 2. Results and discussion 13 was O-alkylated with ethyl 2-bromoacetate in the presence of K2CO3 in DMF to give nitrobenzene derivatives 14. Aniline 2.1. Chemistry derivative 15 was obtained from reduction of 14, and the secondary amines 16a–f were prepared by the N-alkylation of The phenyl-urea derivatives were synthesized by the routes 15 with alkylbromide or aldehydes9. Subsequently, the con- shown in Schemes 1–3. Commercially available p-nitrophenol densation of 16a–f with the 4-nitrophenylcarbamate esters of Novel phenyl-urea derivatives as dual-target ligands that can activate both GK and PPARg 591 Scheme 3 Synthesis of compounds 20a–k. Reagents and conditions: (a) CDI, DMAP, DCM, reflux; (b) k2CO3, MeOH, H2O, 60 1C. Table 1 GK activation effect of compounds 17a–f Table 2 GK activation effect of compounds 18a–f. and GKA22. a a Compd. R1 Activation (fold) Compd. R1 Activation (fold) 17a Cyclopropylmethyl 1.2 18a Cyclopropylmethyl 0.8 17b Cyclohexylmethyl 1.0 18b Cyclohexylmethyl 1.0 17c n-Butyl 1.4 18c n-Butyl 1.3 17d n-Pentyl 1.8 18d n-Pentyl 1.3 17e i-Pentyl 1.2 18e i-Pentyl 1.2 17f 3-Methyl-2-butenyl 1.4 18f 3-Methyl-2-butenyl 0.8 GKA22 1.7 aGK activation (fold) was obtained at a Glc concentration of aGK activation (fold) was obtained at a Glc concentration of 4mM. 4 mM. nitrogen. As shown in Table 1, the potency of compounds with heteroaromatic amines 22 or 23 produced the phenyl-urea acycloalkyl groups viz 17c–f, was superior to compounds with derivatives 17a–f or 18a–f (Scheme 1). Compounds 22 and 23 cycloalkyl groups viz 17a–b. The potency of compounds with were prepared starting from 4-nitrophenyl carbonochloridate straight-chain alkyl groups viz 17c–d, was slightly higher than (Scheme 2). The phenyl-urea derivatives 19a–k were prepared compounds with branched-chain alkyl groups viz 17e–f.Andthe by the three-component condensation of secondary amine 16d, potency of compound with n-pentyl group 17d was the strongest carbonyldiimidazole, and various 2-amino nitrogen heteroaro- in Table 1. matics10. Compounds 20a–k were obtained by the hydroliza- Subsequently, the activation of GK by the compounds 18a–f, bearing a 6-methylbenzothiazole ring replacing the thiazole ring of tion of 19a–k in a methanol–water–K2CO3 system (Scheme 3) 17a–f, was evaluated. As shown in Table 2, the potency of compounds 18a–f was obviously lower than that of the corre- 2.2. In vitro biological activity assay sponding compounds 17a–f. The similar structure–activity rela- tionship noted in Table 1 was observed for compounds 18a–f in The in vitro GK activity assay was performed at 37 1Cfor60min Table 2. in 96-well plates with a final volume of 150 mL reaction mixture AscanbeseenfromTables 1 and 2, replacing the thiazole ring containing 25 mM ATP, 1 mM NAD, 2 mM MgCl2, 5 mM DTT, of 17a–f with a 6-methylbenzothiazole ring had a detrimental 25 mM KCl, 100 mM Tris–HCl, 4.5 unit/mL glucose 6-phosphate effect on potency for GK activation, and the potency of 17a–f was dehydrogenase, 2 unit/mL recombinant GK, 4 mM glucose and notably increased when R1 was n-pentyl group 17d and 18d, test compound. After starting the reaction the increase in whether the nitrogen heteroaromatic moiety was thiazole or absorbance at 340 nm was monitored from 0 to 60 min with a 6-methylbenzothiazole. Subsequently, with R1 as a n-pentyl group, Bio-TEK microplate reader as a measure of GK activity. we explored the effect of a wide range nitrogen heteroaromatic The in vitro activation of GK by the target compounds were groups attached to the secondary urea nitrogen on GK activation evaluated at a concentration 10 mM, and GKA22, a GK efficiency. activator developed by the AstraZeneca11, was used as positive As shown in Table 3, the compound 19a with a pyridine control. The compounds that showed greatest ability to activate ring and 17d with a thiazole ring were equipotent in GK GK were selected for further study and for their ability to activation.

Load more

  10

Copy Link